Press releaseGlobe Newswire
Cognition Therapeutics
CGTX · NASDAQ
$0.7338+$0.0064 (+0.88%)TodayMarket closed ·
Prev close $0.7274
Latest news
- Press releaseGlobe Newswire
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
- Press releaseGlobe Newswire
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
- Press releaseGlobe Newswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
- Press releaseGlobe Newswire
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
- Press releaseGlobe Newswire
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
- Press releaseGlobe Newswire
Cognition Therapeutics Participating in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Press releaseGlobe Newswire
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
Earnings Scheduled For March 26, 2026
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Sapiens International Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsMohd Haider
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
- NewsMohd Haider
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsVandana Singh
Why Is Penny Stock Cognition Therapeutics Trading Over 93% On Wednesday?
- Press releaseGlobe Newswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies
- Press releaseGlobe Newswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
- Press releaseGlobe Newswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
- NewsAvi Kapoor
Dow Edges Lower; Ventyx Biosciences Shares Plummet
- NewsAvi Kapoor
Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
- NewsAvi Kapoor
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
- NewsVandana Singh
Cognition Therapeutics Stock Tumbles On Mixed Data From Mid-Stage Alzheimer's Study
- NewsAvi Kapoor
Nasdaq Gains 1%; McDonald's Posts Downbeat Results
- Press releaseGlobe Newswire
Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients
- NewsAvi Kapoor
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.